Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE CSE Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 75% confidence The document is a Canadian securities regulatory form (NI 45-106F1) titled “Report of Exempt Distribution,” detailing issuer, distribution dates, purchaser breakdowns, exemptions relied upon, compensation, and directors/officers. This is a formal regulatory filing rather than an earnings release, management discussion, or investor presentation. It does not fit specialized categories like share issue announcements (SHA) in the sense of a simple press release but is a detailed SEDAR+ filing. Therefore, it falls under the fallback “Regulatory Filings” category.
2026-04-22 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing facility upgrades, clean room retrofitting, and compliance with regulatory standards for a pharmaceutical manufacturing expansion. It is not an earnings release (no financial results), not a management report, not a share issue, nor a formal regulatory or financial filing. There is no mention of attaching a detailed report, nor is this a proxy, legal, or board change document. It is a general corporate announcement directed at investors and the market. As it does not fit any specific category, it defaults to the Regulatory Filings fallback category (RNS).
2026-04-13 English
News release - English.pdf
Regulatory Filings Classification · 50% confidence The document is a corporate press release announcing facility upgrades and manufacturing expansion at Rapid Dose Therapeutics, containing forward-looking statements and operational details. It does not present financial results, voting items, management changes, dividends, or any formal report attached or published. It is a general corporate announcement that does not fit a more specific category. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2026-04-13 English
News release - English.pdf
Transaction in Own Shares Classification · 88% confidence The document is a press release announcing that Rapid Dose Therapeutics will issue common shares to satisfy accrued interest on its secured convertible notes. This constitutes a direct issuance of the company's own shares (a share issuance event). It is not a fundraising announcement, earnings release, or regulatory report, but specifically a transaction in own shares. Therefore, the correct classification is Transaction in Own Shares (POS).
2026-04-06 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Rapid Dose Therapeutics has begun trading on the OTCQB market. This is a corporate announcement regarding market listing and capital market presence, which does not fit into specific financial reporting categories like 10-K or IR. As it is a general regulatory/corporate announcement, it falls under the RNS (Regulatory Filings) category.
2026-02-11 English
Report of exempt distribution (45-106F1).pdf
Capital/Financing Update Classification · 75% confidence The document is a detailed prospectus summary and term sheet for a new structured notes issuance by Royal Bank of Canada (“RBC Marchés des Capitaux – SOLUTIONS DE PLACEMENT GLOBALES RBC”). It sets out the security’s features, redemption mechanics, coupon, barrier levels, investor subscription details, and legal references to the base prospectus filed with Canadian securities authorities. This is not an annual or interim financial report, nor a board/management change, nor a regulatory announcement of completed votes, but rather an offering document announcing a capital-raising financing by RBC. It most closely fits “Capital/Financing Update (CAP)”.
2026-01-21 French

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.